#USA #Cambridge #Nona Biosciences #Invetx #HCAb Technology

Nona Biosciences and Invetx Collaborate to Advance Animal Health

Nona Biosciences, a leader in biotechnology, has recently announced a strategic partnership with Invetx, a Boston-based animal biotechnology firm. This collaboration aims to develop next-generation biotherapeutics for animal health utilizing Nona's innovative HCAb Harbour Mice® platform.

The Power of the Harbour Mice® Platform

Nona's proprietary Harbour Mice® platform distinguishes itself by producing monoclonal antibodies in both traditional (H2L2) and heavy chain-only (HCAb) formats. The heavy chain-only antibodies are around half the size of standard IgGs, which offers significant advantages for therapeutic applications. This cutting-edge technology is not only globally patented but also clinically validated, setting the stage for revolutionary advancements in antibody therapy for animals.

A New Milestone in Animal Health

Jingsong Wang, MD, PhD, the Chairman of Nona Biosciences, stated that this partnership marks a significant milestone for the company as it ventures into the animal health space for the first time. He emphasized that the versatility of the Harbour Mice® technology enables Nona to contribute to developing novel therapeutics for unmet needs in the animal health arena. With this collaboration, Nona intends to empower Invetx to advance innovative treatments that can improve health outcomes for animals.

Juergen Horn, DVM, PhD, the President of Invetx, expressed excitement about the collaboration. He articulated that by leveraging Nona's heavy chain antibodies, Invetx is poised to expedite the clinical development of animal health therapeutics designed to ensure increased safety and efficacy.

About Nona Biosciences

Nona Biosciences has a robust commitment to innovation and offers integrated solutions that span from ideation to investigational new drug (IND) applications. Their services encompass everything from target validation to antibody discovery, preclinical research, and much more. The Harbour Mice® platform creates fully human monoclonal antibodies using both conventional and heavy chain-only formats, integrating various technologies and expertise in therapeutic antibody discovery.

About Invetx

On the other hand, Invetx is at the forefront of pioneering protein-based therapies aimed at transforming veterinary medicine standards. Equipped with a comprehensive biotechnology platform, Invetx specializes in monoclonal antibodies for veterinary use and is addressing various chronic conditions in companion animals. The company recently became part of Dechra Pharmaceuticals Limited, aligning itself with a global leader in veterinary pharmaceuticals.

With its headquarters in Boston, Invetx continues to build a diverse pipeline addressing critical animal health issues. This partnership with Nona Biosciences is anticipated to accelerate its mission to deliver innovative treatments for animals in need.

In conclusion, the collaboration between Nona Biosciences and Invetx represents not only a strategic business move but also a significant step towards enhancing the therapeutic options available in the field of animal health. As both companies work together, they are set to create impactful solutions that could potentially transform veterinary medicine as we know it.